UNSPSC 51312302: Bufenadrine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Y0T619B3U, chemically known as 2-((o-tert-butyl-alpha-phenyl-benzyl)oxy)-n,n-dimethylethylamine. but generally known as bufenadrine, which bears US NIH Compound Identifier 21916. European Medicines Agency schedules Bufenadrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05959MIG.

UNSPSC 51312302 Bufenadrine (Commodity) does not align with the state and local procurement activity tagged under it. Recent opportunities show state and local governments buying naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through various channels — naloxone procurement by county health departments, cooperative pharmaceutical purchasing through state alliances, and direct-to-manufacturer prescription programs at the state HHS level — but none of these solicitations involve bufenadrine specifically. The code shows a fundamental mismatch between its nominal scope and actual purchasing patterns in the recent opportunities block.

The three recent opportunities reflect different issuing bodies and procurement mechanisms: Seminole County, Florida solicited an IFB for naloxone and drug deactivation systems with a July 26, 2023 response deadline; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with contract effectiveness July 1, 2026; and the Texas Health and Human Services Commission posted an RFI on Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions with an April 3, 2026 response deadline to gather vendor capacity information before formal competitive procurement. The geographic spread includes Florida, Minnesota, Oregon, and Texas, with the cooperative purchasing vehicle indicating participation across multiple state and local jurisdictions. No recent state and local procurement activity under this Commodity code supports bufenadrine as a standalone product line.